Transcatheter Aortic Valve Replacement in Patients With Hypertrophic Obstructive Cardiomyopathy: Toward a Precision-Guided Approach.
The recent study by Almani et al. [1] provides an important contribution to understanding risk in transcatheter aortic valve replacement (TAVR). Among nearly 300,000 patients, only 0.2% had hypertrophic obstructive cardiomyopathy (HOCM), yet this subgroup showed markedly worse in-hospital outcomes, including a threefold increase in mortality and higher rates of atrioventricular block, cardiogenic shock, and acute kidney injury. These findings remind interventional cardiologists that procedural success in TAVR depends not only on anatomical precision but also on ventricular physiology [2]. The authors appropriately highlight the hemodynamic complexity of patients with combined fixed and dynamic obstruction. These results, however, invite reflection on the importance of diagnostic precision before intervention. In daily practice, patients with left ventricular hypertrophy and aortic stenosis often fall into a diagnostic gray zone. The key question is whether the hypertrophy represents a secondary adaptation to valvular overload or an underlying cardiomyopathy. This distinction has major therapeutic implications. When hypertrophic cardiomyopathy (HCM) coexists or predominates, other strategies such as surgical septal myectomy, often combined with valve replacement, or alcohol septal ablation may offer more physiologically appropriate solutions than isolated TAVR. Accurate identification of HCM before TAVR is therefore not merely an academic concern but one that can alter the treatment pathway entirely. Multimodality imaging, particularly cardiac magnetic resonance, is essential to detect asymmetric hypertrophy, systolic anterior motion, or midventricular obstruction. Even so, imaging findings can overlap in older patients with long-standing hypertension or calcific aortic stenosis, making differentiation difficult. In such cases, complementary tools such as targeted genetic testing may refine diagnosis and guide referral toward the most appropriate therapy [3]. This approach represents a practical expression of precision medicine, where clinical and molecular information combine to ensure that the chosen intervention aligns with the underlying disease. Recent imaging studies support the biological basis of this differentiation. Chung et al. [4] demonstrated that carriers of sarcomere mutations exhibit significantly greater myocardial fibrosis than genotype-negative counterparts, with 90% showing late gadolinium enhancement compared with 60% among noncarriers (p < 0.001). Even in myocardial regions without visible enhancement, extracellular volume was higher (32.4% vs. 30.7%, p = 0.025), confirming diffuse interstitial fibrosis. This fibrotic substrate increases stiffness and reduces compliance, limiting the heart′s ability to tolerate abrupt unloading. Such pathophysiology helps explain why ventricles with hypertrophic cardiomyopathy are prone to post-TAVR collapse and instability despite technically successful implantation. Although genetic testing is not part of routine pre-TAVR evaluation, it could be selectively applied to patients with disproportionate septal thickening or dynamic gradients. Identifying a sarcomeric substrate before intervention could inform the choice between TAVR and surgical strategies or justify septal reduction before transcatheter valve replacement. Ultimately, the study by Almani et al. highlights that outcomes after TAVR depend not only on device technology but on accurate disease characterization. In patients with unexplained or asymmetric hypertrophy, comprehensive evaluation that includes consideration of hypertrophic cardiomyopathy and potential septal reduction should precede transcatheter intervention. The convergence of imaging, myocardial biology, and clinical judgment defines the future of precision-guided structural cardiology, ensuring that valve replacement treats the disease mechanism rather than its manifestation. The authors declare no conflicts of interest.
Read more